PRQR proqr.com: יחס שווי שוק לערך בספרים

The ProQR Therapeutics N.V. (PRQR) licensing platform generates a steady cash flow, as confirmed by the price action chart at the 2.07 level. The business relies on advanced RNA editing methods to combat genetic pathologies, including the treatment of vision loss. Process efficiency is supported by precise cold-chain drug transportation, which guarantees component integrity and high distribution margins.

To build a high-quality portfolio, it is essential to track the price-to-book ratio, which measures the premium for future growth relative to current capital. For ProQR Therapeutics N.V. (PRQR), whose model is based on the full outsourcing of production and R&D, the extent to which market capitalization exceeds book value reflects the value of intellectual property and patents rather than tangible assets.